240 related articles for article (PubMed ID: 23514878)
1. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
2. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M
Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
4. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
[TBL] [Abstract][Full Text] [Related]
5. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis.
Boyle M; Ting A; Cury DB; Nanda K; Cheifetz AS; Moss A
Inflamm Bowel Dis; 2015 Dec; 21(12):2873-8. PubMed ID: 26313693
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
8. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
Gillespie D; Hood K; Farewell D; Stenson R; Probert C; Hawthorne AB
Inflamm Bowel Dis; 2014 Jan; 20(1):82-91. PubMed ID: 24284414
[TBL] [Abstract][Full Text] [Related]
9. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
10. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
Bresci G; Parisi G; Capria A
Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
[TBL] [Abstract][Full Text] [Related]
11. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
12. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
13. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Hanauer SB; Sandborn WJ; Dallaire C; Archambault A; Yacyshyn B; Yeh C; Smith-Hall N
Can J Gastroenterol; 2007 Dec; 21(12):827-34. PubMed ID: 18080055
[TBL] [Abstract][Full Text] [Related]
14. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
[TBL] [Abstract][Full Text] [Related]
15. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
Higgins PD; Rubin DT; Kaulback K; Schoenfield PS; Kane SV
Aliment Pharmacol Ther; 2009 Feb; 29(3):247-57. PubMed ID: 18945258
[TBL] [Abstract][Full Text] [Related]
17. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
18. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
Patient; 2012; 5(1):33-44. PubMed ID: 22077619
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
